Otsuka Of Japan Acquires Interpharma Praha Of Czech Republic
This article was originally published in PharmAsia News
Executive SummaryJapan's Otsuka Pharmaceutical says it has acquired the Czech Republic company Interpharma Praha and its expertise in contrast agents for X-rays. The agents would comprise a new product line for Otsuka in a segment of the market that is growing along with the global popularity of CT scans. Otsuka plans to use Interpharma in an effort to expand its presence in Europe, but plans to concentrate on selling the contrast agents in Russia. Interpharma had more than $9.1 million in sales in fiscal 2007. (Click here for more - a subscription may be required
You may also be interested in...
Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.
House passes Democratic bill authorizing the federal government to negotiate drug prices in Medicare. While the exercise has sharpened the debate over how prices feed innovation, the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Our table highlights the key provisions of HR 3 and other pending pricing legislation.
The new Eudamed database may be delayed for two years, but the European Commission wants to allow early access to Single Registration Numbers before Eudamed goes live in 2022 to aid voluntary registration in the interim.